These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38230990)

  • 41. A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
    Hainsworth JD; Arrowsmith ER; McCleod M; Hsi ED; Hamid O; Shi P; Lin BK; Fayad LE
    Leuk Lymphoma; 2016; 57(1):216-8. PubMed ID: 25956042
    [No Abstract]   [Full Text] [Related]  

  • 42. Frontline therapy with R-CHOP for diffuse large B-cell lymphoma: Where have we come (or not come)? A Perspective.
    Morrison VA
    J Geriatr Oncol; 2021 Mar; 12(2):320-325. PubMed ID: 32972884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Till BG
    Curr Treat Options Oncol; 2018 Jul; 19(9):45. PubMed ID: 30032463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
    Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
    Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
    Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C
    Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
    Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
    Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
    Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
    Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
    Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
    Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
    Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
    Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.
    Snider JT; McMorrow D; Song X; Diakun D; Wade SW; Cheng P
    Clin Ther; 2022 Apr; 44(4):521-538. PubMed ID: 35241295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
    Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
    Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
    [No Abstract]   [Full Text] [Related]  

  • 54. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
    Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
    Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma.
    Xiao Z; Li J; Miao K
    Curr Stem Cell Res Ther; 2017; 12(1):14-18. PubMed ID: 27396370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
    Fitoussi O; Belhadj K; Mounier N; Parrens M; Tilly H; Salles G; Feugier P; Ferme C; Ysebaert L; Gabarre J; Herbrecht R; Janvier M; Van Den Neste E; Morschhauser F; Casasnovas O; Ghesquieres H; Anglaret B; Brechignac S; Haioun C; Gisselbrecht C
    Haematologica; 2011 Aug; 96(8):1136-43. PubMed ID: 21546499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma.
    Camus V; Tilly H
    Expert Rev Hematol; 2017 Dec; 10(12):1047-1055. PubMed ID: 27791447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
    Yan X; Zhou M; Lou Z; Mu Q; Sheng L; Zhang P; Wang Y; Ouyang G
    J Cancer Res Ther; 2018; 14(Supplement):S248-S253. PubMed ID: 29578182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
    Tian C; Chen Z; Li Y
    J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.